Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
News|Articles|September 20, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-10-04-2017
- Volume 12
- Issue 10
Spectrum Chemical in Distribution Deal with Cole-Parmer
Author(s)Pharmaceutical Technology Editors
Spectrum Chemical announced an agreement with Cole-Parmer for the distribution of Spectrum’s USP fine chemicals.
Advertisement
On Sep. 20, 2017, Spectrum Chemical, a manufacturer and distributor of fine chemicals, laboratory equipment, and supplies, announced a distribution agreement with Cole-Parmer, a manufacturer and distributor of fluid handling products, instrumentation, equipment, and supplies. Under the agreement, Cole Parmer will distribute Spectrum’s USP fine chemicals.
“The addition of Cole-Parmer to our distribution network adds laboratory instrument expertise and brand strength to our portfolio,” said Randy Burg, president and CEO of Spectrum, in a company press release.
Brian Buzinski, director of lab essentials business unit at Cole Parmer added, “As a trusted name in quality chemicals for more than four decades, we are happy to now offer Spectrum products to Cole-Parmer’s customers.”
Source:
Articles in this issue
almost 9 years ago
Finding a New Purpose for an Unproven Drugalmost 9 years ago
Demand for Efficiency Spurs Bioprocessing Innovationalmost 9 years ago
Fresenius Kabi Breaks Ground on $250-Million Facility Expansionabout 9 years ago
UPS Reveals Supply Chain Security Systemabout 9 years ago
Cambrex Adds Reactors to Facility in Swedenabout 9 years ago
ADC Bio Invests $11 Million on Bioconjugation Facilityabout 9 years ago
Software Adds Data Integrity Functionsabout 9 years ago
Particle Analyzer Images Nanoparticlesabout 9 years ago
Global Effort to Stop Sale of Illegal Drugs Advancesabout 9 years ago
BASF Plans Amine Facility in NanjingAdvertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
PharmTech’s Weekly Roundup—September 25, 2026
4
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
5